NIH statement on preliminary efficacy results of twice-yearly lenacapavir for HIV prevention in cisgender women
The injectable antiretroviral drug lenacapavir was safe and 100% effective as long-acting HIV pre-exposure prophylaxis (PrEP) among cisgender women in a Phase 3 clinical trial,...